Gd HP-DO3A--experimental evaluation in brain and renal MR.
GD HP-DO3A, a neutral (nonionic) IV MR contrast agent presently in clinical trials, was evaluated with respect to imaging characteristics in rats. Following administration of 0.25 mmol/kg I.V., 58 +/- 19%, i.e. (n = 6) enhancement was noted in a brain gliosarcoma model. Meningeal spread of neoplasia could be identified due to its enhancement (69 +/- 26%) in nine animals. The time course of renal enhancement was quantitated at two dosages, 0.05 (n = 4) and 0.25 mmol/kg (n = 8). At the higher dose, enhancement of both cortex and medulla plateaued between 9 and 23 min postinjection. At the lower dose, enhancement of renal medulla was maximum at 2 min postinjection. These enhancement characteristics (both brain and kidney), at equivalent contrast dosages, are comparable to that previously published for Gd-DTPA. However, Gd HP-DO3A has the potential to be utilized clinically at higher doses than Gd-DTPA, with no reported adverse effects in initial trials employing up to 0.3 mmol/kg.
Runge
V M
VM
Department of Radiology, University of Kentucky Medical Center, Lexington 40536.
Gelblum
D Y
DY
Jacobson
S
S
D000818:Animals; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000473:pathology; D003287:Contrast Media / Q000008:administration & dosage; D005682:Gadolinium / Q000008:administration & dosage; D019786:Gadolinium DTPA; D005910:Glioma / Q000175:diagnosis / Q000473:pathology; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D007089:Image Enhancement / Q000379:methods; D007668:Kidney / Q000033:anatomy & histology*; D007672:Kidney Cortex / Q000033:anatomy & histology; D007679:Kidney Medulla / Q000033:anatomy & histology; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000473:pathology; D008961:Models, Structural; D009942:Organometallic Compounds / Q000008:administration & dosage; D004369:Pentetic Acid / Q000008:administration & dosage; D051381:Rats; D011916:Rats, Inbred F344; D013997:Time Factors
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D004369:Pentetic Acid; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D005682:Gadolinium; D019786:Gadolinium DTPA